🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-523641-10-00
Completed Phase I

PHARMACOKINETICS OF PETRELINTIDE FOLLOWING ADMINISTRATION TO PARTICIPANTS WITH IMPAIRED HEPATIC FUNCTION

2025-523641-10-00 · tracked via the Priya Life Science EU tracker
Sponsor
Zealand Pharma A/S
Sponsor type
Pharmaceutical company
Therapeutic area
Not possible to specify
Decision date
06/05/2026
Enrollment target
36
Sites
Slovakia, Poland

Condition studied

Healthy / hepatic impaired volunteers only study to assess PK parameters

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523641-10-00 on CTIS ↗ ← All trials in the EU